Drugs / Adipose-derived MSCs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03818737 | Mar 2019 → May 2022 | osteoarthritis | Emory University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose-derived MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818737 ↗ |
| Modality | Cell therapy | “The potential of mesenchymal stem cells (MSCs) to inhibit inflammation while promoting healing makes them amenable for the treatment of various ailments ranging from cancer to...” NCT03818737 ↗ |
| Route | Other | “will be injected into the knee joint” NCT03818737 ↗ |